• Mashup Score: 0
    Oral paclitaxel regimen improves outcomes vs. IV formulation in metastatic breast cancer - 4 year(s) ago

    Hemonc Today | SAN ANTONIO — A novel combination of oral paclitaxel plus encequidar significantly improved overall response rates compared with IV paclitaxel among women with metastatic breast cancer, according to results of a randomized phase 3 study presented at San Antonio Breast Cancer Symposium.“We wanted to have an oral taxane agent available that we knew to be safe and widely used [for

    Source: www.healio.com
    Categories: Hem/Onc News and Journals
    Tweet Tweets with this article
    • Profile photo of HemOncToday
      HemOncToday

      #SABCS19 - Oral paclitaxel improves outcomes vs. IV formulation in metastatic breast cancer, says research from Gerardo Antonio Umanzor Funez @agenciasanluis https://t.co/HwMAEZmphY

  • Mashup Score: 0
    Phase III Study of Oral Paclitaxel in Metastatic Breast Cancer #SABCS19 - 4 year(s) ago

    Gerardo Antonio Umanzor, MD of Liga Contra el Cáncer on paclitaxel shown to be superior to IV paclitaxel on confirmed response and survival with less neuropathy: a Phase III clinical study in metastatic breast cancer.

    Source: www.oncologytube.com
    Categories: Hem/Onc News and Journals
    Tweet Tweets with this article
    • Profile photo of oncologytube
      oncologytube

      Phase III Study of Oral Paclitaxel in Metastatic Breast Cancer #SABCS19: Gerardo Antonio Umanzor, MD of Liga Contra el Cáncer on paclitaxel shown to be superior to IV paclitaxel on confirmed response and survival with less neuropathy: a Phase III… https://t.co/0QgU5zetTu https://t.co/UxcWIVm1f3

  • Mashup Score: 0
    SOHPIA Study in Metastatic Breast Cancer #SABCS19 @UCSFMedicine - 4 year(s) ago

    Hope Rugo, MD of @UCSFMedicine discusses the SOPHIA Study.

    _____________

    MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today presented updated results from the Phase 3 SOPHIA study comparing margetuximab plus chemotherapy versus…

    Source: www.oncologytube.com
    Categories: Hem/Onc News and Journals
    Tweet Tweets with this article
    • Profile photo of oncologytube
      oncologytube

      SOHPIA Study in Metastatic Breast Cancer #SABCS19 @UCSFMedicine: Hope Rugo, MD of @UCSFMedicine discusses the SOPHIA Study. _____________ MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing… https://t.co/xeZwn2rpEp https://t.co/8XVDRwdUBZ

  • Mashup Score: 0
    Prognostic Marker in Operable Breast Cancer #SABCS19 - 4 year(s) ago

    Luca Malorni, MD of Prato Hospital discusses a marker in operable breast cancer at SABCS 19.

    __________

    The study is a retrospective analysis on serum samples from a randomized clinical trial comprising 644 women with operable breast cancer (premenopausal with stage II-IIIB HR+ breast cancer). Serum samples were collected pre-operatively on the day of surgery.

    After…

    Source: www.oncologytube.com
    Categories: Hem/Onc News and Journals
    Tweet Tweets with this article
    • Profile photo of oncologytube
      oncologytube

      Prognostic Marker in Operable Breast Cancer #SABCS19: Luca Malorni, MD of Prato Hospital discusses a marker in operable breast cancer at SABCS 19. __________ The study is a retrospective analysis on serum samples from a randomized clinical trial… https://t.co/mXPa8xNx4L https://t.co/WFZ1aRfjWE

  • Mashup Score: 0
    Prognostic Marker in Operable Breast Cancer: How This Affects Clinicians? #SABCS19 - 4 year(s) ago

    Luca Malorni, MD of Prato Hospital discusses a marker in operable breast cancer at SABCS 19.

    __________

    The study is a retrospective analysis on serum samples from a randomized clinical trial comprising 644 women with operable breast cancer (premenopausal with stage II-IIIB HR+ breast cancer). Serum samples were collected pre-operatively on the day of surgery.

    After…

    Source: www.oncologytube.com
    Categories: Hem/Onc News and Journals
    Tweet Tweets with this article
    • Profile photo of oncologytube
      oncologytube

      Prognostic Marker in Operable Breast Cancer: How This Affects Clinicians? #SABCS19: Luca Malorni, MD of Prato Hospital discusses a marker in operable breast cancer at SABCS 19. __________ The study is a retrospective analysis on serum samples from a… https://t.co/bUvbpGIMXx https://t.co/GdYaRFIxCW

Load More